»Print   »Share   »Bookmark

All Cancers/Any Site

  • EAY131 (NCI-MATCH): Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
  • ECOG EAQ152: COMET-Communication and Education in Tumor Profiling
  • UW15068: UWCCC Precision Medicine Molecular Tumor Board Registry
  • UW16029: Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice

Breast Cancer

Adjuvant:

  • Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer : The ABC Trial
  • SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
  • NSABP B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
  • NRG BR-003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • PrECOG PrE0109 (PALLAS): Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy vs. Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive/Human Epidermal Growth Receptor 2 (HER2) negative Early Breast Cancer

Neo-Adjuvant:

  • NSABP B-51/RTOG 1304: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
  • SWOG S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Metastatic/Advanced Disease:

  • ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
  • ECOG EAI142: (18F) Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer

Miscellaneous:

  • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Breast Screening Trials:

  • ECOG EA1141: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Gastrointestinal Cancer

Colon/Rectal:

Pancreatic:

  • SWOG S1505: A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

  • SWOG S1513: Randomized Phase II Study of 2nd Line FOLFIRI vs. Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) in Metastatic Pancreatic Cancer

 

Genetics

  • City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
  • Genomic Medicine Institute - Cancer Specimen Banking: Molecular Mechanisms Involved in Cancer Predisposition
  • ECOG EAQ152 (COMET) - Communication and Education in Tumor Profiling. A Randomized Study of Pre-Disclosure Genetic Education vs. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling. 

Genitourinary Cancer

Kidney (Renal):

  • ECOG E2810:   Randomized, Double-Blind Phase III Study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

 

Gynecological Cancer:

Cervical:

  • GOG 0278: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) For Stage 1A1 (LVSI+) And IA2-IB1 (equal or less than 2cm) Cervical Cancer

Endometrial:

  • GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Ovarian/Fallopian Tube:

  • NRG-GY004: Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • NRG-GY005: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • University of Southern Alabama / MCI GON: A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

Hematology Cancer:

Leukemia

Acute Myeloid Leukemia (AML):

  • ECOG E2906: Phase III Randomized Trial of Clofarabine as Induction and Post Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction adn Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (>/= 60 years old)

Chronic Lymphocytic Leukemia (CLL):

  • InformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Lymphoma

Diffuse Large B-Cell Lymphoma:

  • ECOG E1412: Randomized Phase II Open Label Study of Lenalidomide R-Chop (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Follicular/Marginal Zone/Mantle Cell Lymphoma:

  • Celgene CC-5013-NHL-008 (Magnify): A Phase IIIB Randomized Study of Lenalidomide (CC-5013) + Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance vs. Rituximab Maintenance in Submjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Mantle Cell:

  • ECOG E1411: Intergroup Randomized Phase II Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Foll

Multiple Myeloma:

  • ECOG E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
  • Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy.

Myelodysplastic Syndrome (MDS)/Anemia:
 

  • ConnectMDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Registry
  • AZA-MDS-003: Phase III Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine + Best Supportive Care vs. Placebo + Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes

Lung Cancer

Non-Small Cell Lung Cancer (NSCLC):

  • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery
  • RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
  • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • ECOG EA5142: Adjuvant Nivolumab in Resected Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Squamous Cell Lung Cancer:

  • SWOG S1400: Phase II/III Biomarket-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Skin Cancer

  • ECOG EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilumumab plus Sargramstim versus Nivolumab plus Ipilumumab in Patients with Unresectable Stage III or Stage IV Melanoma.
  • ECOG E3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • SWOG S1320: A Randomized, Phase II Trial of INtermittent vs. Continuous Dosing of Dabrafenib and Trametinib in BRAF Mutant Melanoma

Neurological/Brain Cancer

Glioblastoma Multiforme (GBM)

Newly Diagnosed:

Low Grade Glioma:

  • NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
  • OT-15-001: Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy.

Meningiomas:

  • Alliance A071401- Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Symptom Management:

  • Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
  • EAP-001: An Open-Label, Expanded Access Protocol for Firdapse Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus.